Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 126.1
(-0.98%)
INR 126.1
(-0.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.73 Billion INR | -97.9% |
| 2022 | -2.03 Billion INR | -9.67% |
| 2021 | -1.79 Billion INR | -41.86% |
| 2020 | -1.29 Billion INR | 57.47% |
| 2019 | -3 Billion INR | -111.57% |
| 2018 | -1.37 Billion INR | 39.99% |
| 2017 | -1.88 Billion INR | -119.45% |
| 2016 | -1.08 Billion INR | -83.1% |
| 2015 | -599.77 Million INR | -86.55% |
| 2014 | -317.83 Million INR | -182.99% |
| 2013 | 437.72 Million INR | 342.28% |
| 2012 | -148.7 Million INR | 76.68% |
| 2011 | -687.94 Million INR | -1177.57% |
| 2010 | -53.94 Million INR | 71.04% |
| 2009 | -187.69 Million INR | -78.59% |
| 2008 | -101.69 Million INR | -209.98% |
| 2007 | -33.3 Million INR | -93.27% |
| 2006 | -17.34 Million INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -933.6 Million INR | 9.49% |
| 2024 Q2 | -1.02 Billion INR | -12.06% |
| 2023 Q4 | -1.05 Billion INR | -9.98% |
| 2023 Q3 | -962.3 Million INR | -15.97% |
| 2023 Q2 | -829.8 Million INR | 9.79% |
| 2023 Q1 | -919.9 Million INR | -16.68% |
| 2023 FY | - INR | -97.9% |
| 2022 Q3 | 162.1 Million INR | 125.92% |
| 2022 Q1 | -780.2 Million INR | -17.65% |
| 2022 FY | - INR | -9.67% |
| 2022 Q4 | -788.4 Million INR | -586.37% |
| 2022 Q2 | -625.4 Million INR | 19.84% |
| 2021 Q2 | -491.9 Million INR | 8.0% |
| 2021 Q4 | -663.14 Million INR | -506.72% |
| 2021 Q1 | -534.7 Million INR | -6.74% |
| 2021 Q3 | -109.3 Million INR | 77.78% |
| 2021 FY | - INR | -41.86% |
| 2020 Q2 | -795.5 Million INR | -229.48% |
| 2020 Q3 | -613.6 Million INR | 22.87% |
| 2020 FY | - INR | 57.47% |
| 2020 Q4 | -500.95 Million INR | 18.36% |
| 2020 Q1 | 614.4 Million INR | 164.51% |
| 2019 Q4 | -952.38 Million INR | -79.69% |
| 2019 Q3 | -530 Million INR | 12.63% |
| 2019 FY | - INR | -111.57% |
| 2019 Q1 | -913.5 Million INR | -515.74% |
| 2019 Q2 | -606.6 Million INR | 33.6% |
| 2018 FY | - INR | 39.99% |
| 2018 Q1 | -625.6 Million INR | -40.68% |
| 2018 Q3 | -671 Million INR | -10550.79% |
| 2018 Q4 | -148.35 Million INR | 77.89% |
| 2018 Q2 | -6.3 Million INR | 98.99% |
| 2017 Q4 | -444.7 Million INR | 20.63% |
| 2017 FY | - INR | -119.45% |
| 2017 Q3 | -560.3 Million INR | 7.34% |
| 2017 Q2 | -604.7 Million INR | 21.17% |
| 2017 Q1 | -767.1 Million INR | -154.34% |
| 2016 Q1 | -331.2 Million INR | -424.05% |
| 2016 FY | - INR | -83.1% |
| 2016 Q4 | -301.6 Million INR | 53.03% |
| 2016 Q3 | -642.1 Million INR | -471.59% |
| 2016 Q2 | 172.8 Million INR | 152.17% |
| 2015 Q3 | -384.6 Million INR | -145.12% |
| 2015 Q4 | -63.2 Million INR | 83.57% |
| 2015 FY | - INR | -86.55% |
| 2015 Q1 | 2.2 Million INR | 102.91% |
| 2015 Q2 | -156.9 Million INR | -7231.82% |
| 2014 Q3 | -170.5 Million INR | -2764.06% |
| 2014 Q1 | -80.8 Million INR | -292.96% |
| 2014 Q4 | -75.72 Million INR | 55.59% |
| 2014 FY | - INR | -182.99% |
| 2014 Q2 | 6.4 Million INR | 107.92% |
| 2013 Q3 | 374.3 Million INR | 899.79% |
| 2013 Q1 | 128 Million INR | -72.63% |
| 2013 FY | - INR | 342.28% |
| 2013 Q4 | -20.56 Million INR | -105.49% |
| 2013 Q2 | -46.8 Million INR | -136.56% |
| 2012 Q2 | -225.4 Million INR | -29.76% |
| 2012 Q1 | -173.7 Million INR | 16.11% |
| 2012 FY | - INR | 76.68% |
| 2012 Q4 | 467.61 Million INR | 312.55% |
| 2012 Q3 | -220 Million INR | 2.4% |
| 2011 FY | - INR | -1177.57% |
| 2011 Q4 | -207.05 Million INR | -21.51% |
| 2011 Q3 | -170.4 Million INR | 0.0% |
| 2010 FY | - INR | 71.04% |
| 2009 FY | - INR | -78.59% |
| 2008 FY | - INR | -209.98% |
| 2007 FY | - INR | -93.27% |
| 2006 FY | - INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | 8361.855% |
| Aarti Drugs Limited | 3.24 Billion INR | 214.863% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 195.448% |
| Ajanta Pharma Limited | 12.56 Billion INR | 129.696% |
| Alembic Limited | 1.11 Billion INR | 434.259% |
| Alkem Laboratories Limited | 24.19 Billion INR | 115.422% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 138.802% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 258.328% |
| Bal Pharma Limited | 345.59 Million INR | 1179.732% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | 28812.427% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 352.292% |
| Brooks Laboratories Limited | 41.72 Million INR | 9042.358% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | 3356.562% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 160.343% |
| Divi's Laboratories Limited | 25.43 Billion INR | 114.673% |
| Eris Lifesciences Limited | 6.98 Billion INR | 153.41% |
| Granules India Limited | 8.6 Billion INR | 143.37% |
| Ind-Swift Limited | 1.06 Billion INR | 450.351% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 1253.61% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 139.974% |
| Jubilant Pharmova Limited | 8 Billion INR | 146.608% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 1398.24% |
| Medicamen Biotech Limited | 245.66 Million INR | 1618.956% |
| Medico Remedies Limited | 129.09 Million INR | 2990.504% |
| Wockhardt Limited | 1.08 Billion INR | 445.506% |
| Orchid Pharma Limited | 1.41 Billion INR | 362.931% |
| RPG Life Sciences Limited | 1.28 Billion INR | 391.18% |
| Shilpa Medicare Limited | 2.58 Billion INR | 244.184% |
| Sigachi Industries Limited | 883.39 Million INR | 522.399% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | -32.232% |
| Unichem Laboratories Limited | 742.35 Million INR | 602.652% |
| Vaishali Pharma Limited | 31.71 Million INR | 11867.106% |
| Wanbury Limited | 985.49 Million INR | 478.641% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 106.637% |
| FDC Limited | 3.38 Billion INR | 210.223% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 647.46% |
| Bajaj HealthCare Limited | 406.23 Million INR | 1018.542% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 104.227% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 154.372% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 154.382% |
| Laurus Labs Limited | 8 Billion INR | 146.608% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 2232.925% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 342.999% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | 1735.36% |
| Hester Biosciences Limited | 539.47 Million INR | 791.691% |
| Ipca Laboratories Limited | 13.29 Billion INR | 128.057% |
| Venus Remedies Limited | 711.8 Million INR | 624.229% |
| ZIM Laboratories Limited | 462.09 Million INR | 907.507% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 106.039% |
| Morepen Laboratories Limited | 1.72 Billion INR | 316.197% |
| Neuland Laboratories Limited | 4.74 Billion INR | 178.587% |
| Sequent Scientific Limited | 549.8 Million INR | 778.695% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 179.78% |
| Valiant Laboratories Limited | 12.73 Million INR | 29391.679% |
| Windlas Biotech Limited | 781.72 Million INR | 577.341% |
| Hikal Limited | 2.69 Billion INR | 238.601% |
| Innova Captab Limited | 1.66 Billion INR | 323.667% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 221.372% |
| Themis Medicare Limited | 562.6 Million INR | 763.246% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 243.155% |
| Mankind Pharma Limited | 28.09 Billion INR | 113.282% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 132.895% |
| Sakar Healthcare Limited | 393.26 Million INR | 1048.836% |
| Albert David Limited | 1.04 Billion INR | 456.934% |
| Lupin Limited | 36.96 Billion INR | 110.093% |
| Gufic Biosciences Limited | 1.48 Billion INR | 352.043% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 102.697% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 377.779% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 967.226% |
| Piramal Enterprises Limited | -3.86 Billion INR | 3.357% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 110.658% |
| NATCO Pharma Limited | 18.79 Billion INR | 119.854% |
| Suven Life Sciences Limited | -992.78 Million INR | -275.86% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | -4410.579% |
| Strides Pharma Science Limited | 3.76 Billion INR | 199.118% |
| Indoco Remedies Limited | 2.64 Billion INR | 240.967% |
| Alpa Laboratories Limited | 229.96 Million INR | 1722.652% |
| Lasa Supergenerics Limited | -65.08 Million INR | -5633.662% |